Company Overview - Sichuan Kelun Pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on May 29, 2002, and listed on June 3, 2010. The company specializes in the development, production, and sales of large-volume parenteral solutions [1][2] - The main business revenue composition includes: non-infusion products 48.37%, infusion products 41.28%, R&D projects 7.01%, and others 3.33% [1] Financial Performance - For the first half of 2025, Kelun Pharmaceutical achieved operating revenue of 9.083 billion yuan, a year-on-year decrease of 23.20%. The net profit attributable to shareholders was 1.001 billion yuan, down 44.41% year-on-year [2] - Since its A-share listing, the company has distributed a total of 6.697 billion yuan in dividends, with 3.386 billion yuan distributed in the last three years [3] Stock Market Activity - On September 24, Kelun Pharmaceutical's stock price increased by 2.00%, reaching 37.69 yuan per share, with a trading volume of 1.05 billion yuan and a turnover rate of 0.22%. The total market capitalization is 60.231 billion yuan [1] - Year-to-date, the stock price has risen by 28.07%, with a 2.03% increase over the last five trading days, 2.14% over the last twenty days, and 6.14% over the last sixty days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on April 30, where the net buying amount was 31.8792 million yuan [1] Shareholder Structure - As of June 30, 2025, the number of shareholders is 34,200, an increase of 2.55% from the previous period. The average circulating shares per person decreased by 2.49% to 38,138 shares [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]

【导读】多位知名公募基金经理参与百利天恒新股增发 当前，在创新药板块经历震荡调整之际，葛兰、赵蓓和朱少醒等多位知名基金经理出手，参与创新药龙头公司百利天恒增发。 葛兰、赵蓓再次出手 中欧基金葛兰和工银瑞信基金赵蓓旗下基金分别以约6.79亿元、2.79亿元认购百利天恒定增。 9月23日，中欧基金公告显示，葛兰管理的中欧医疗健康混合基金认购百利天恒185.59万股，成本共计5.88亿元；中欧医疗创新股票基金认购百利天恒 28.55万股，成本共计9050.98万元。 | 认购数量 | | 总成本 占基金 | | 账面价 值占基 | 锁定 | | --- | --- | --- | --- | --- | --- | | 基金名称 | 总成本(元) | | 账面价值(元) | 金资产 | | | (股) | | 资产净 | | | 期 | | | | 值比例 | | 浄值比 | | | | | | | 例 (%) | | | | | (%) | | | | | 中欧医疗健康混合 1,855,877 型证券投资基金 | 588.313.009.00 1.7964 | | 634. 171. 729. 67 | 1. 9 ...

美联储于9月18日如期宣布降息25bp，为港股市场提供了较为宽松的流动性环境。但当前距离10月29日 议息尚有35天，美联储相关官员的发言在短期内引起较大扰动。 展望后市，市场预期年内还将有两次降息。据CME FedWatch Tool数据，美联储10月降息25bp的概率为 91.9%；12月降息25bp的概率为21.7%，降息50bp的概率为77%。 每日经济新闻 中邮证券表示，创新药当前处于相对高位，震荡在所难免，需要把握真正优质创新资产；国内创新药景 气度基本见底，后续研发需求有望兑现到CRO行业业绩。 从二级市场来看，聚焦港股市场创新药+CXO的恒生医药ETF（159892）连续调整，自阶段高点回落近 6%。其持仓股映恩生物今日领跌，三生制药、再鼎医药、云顶新耀、亚盛医药等跌幅靠前。 ...

Core Insights - Eddie Pharmaceuticals' stock price increased by 2.20% on September 24, reaching 14.87 CNY per share, with a market capitalization of 6.257 billion CNY [1] - The company has seen a year-to-date stock price increase of 89.19%, but has experienced a decline of 2.11% over the last five trading days and 11.86% over the last twenty days [1] - For the first half of 2025, Eddie Pharmaceuticals reported a revenue of 362 million CNY, representing a year-on-year growth of 100.19%, and a net profit of 9.191 million CNY, up 120.23% year-on-year [2] Company Overview - Eddie Pharmaceuticals, established on December 15, 2009, and listed on July 20, 2020, is based in Yangzhou, Jiangsu Province [1] - The company's main business involves the exploration, research, and sales of innovative chemical drugs and human-derived protein products, with revenue composition as follows: human-derived protein 41.11%, new drugs 35.69%, diagnostic equipment and reagents 13.62%, generic drugs 9.47%, and others 0.11% [1] - As of June 30, 2025, the number of shareholders increased by 34.45% to 11,900, while the average circulating shares per person decreased by 25.62% to 35,247 shares [2] Financial Performance - Since its A-share listing, Eddie Pharmaceuticals has distributed a total of 20.16 million CNY in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders include Penghua Medical Technology Stock A and new entrants such as招商行业精选股票 and 广发价值核心混合A, indicating a shift in institutional holdings [3]

Group 1 - The article highlights significant investments by prominent fund managers in the innovative drug company Bai Li Tian Heng during a recent market adjustment in the pharmaceutical sector [3][11][15] - Fund manager Ge Lan's two funds invested a total of 6.79 billion yuan in Bai Li Tian Heng's private placement, indicating strong confidence in the company's growth potential [3][11] - The funds managed by Ge Lan have been increasing their holdings in Bai Li Tian Heng over the past year, with the total shares held rising to 427.97 million by the second quarter of this year [6][9] Group 2 - Bai Li Tian Heng's recent private placement raised 3.764 billion yuan by issuing 11.8738 million shares at a price of 317 yuan each, with several well-known fund managers participating [11][12] - The funds involved in the placement include those managed by Zhu Shaoxing and Fan Yan, among others, reflecting a broader institutional interest in the innovative drug sector [11][15] - The innovative drug sector continues to attract significant capital inflows, with various ETFs seeing substantial net subscriptions despite recent market adjustments [15][16] Group 3 - The article discusses the long-term growth potential of China's innovative drug industry, which is expected to experience explosive growth in the global market [16] - China's drug development capabilities are gaining international recognition, with the country ranking second globally in the number of drugs under development [16] - Recent policy changes are creating a favorable environment for the innovative drug sector, despite short-term volatility [16]

Investment Rating - Industry rating: Positive [1] Core Viewpoints - The report highlights the strong performance of stock prices and the improvement in profitability within the innovative drug sector [3] - The valuation is expected to break through due to the "engineer dividend" and continuous high-intensity R&D investment [4][5] Summary by Sections Review: Strong Stock Prices and Profitability Improvement - Stock prices have shown a strong upward trend, driven by business development (BD) and clinical data [12] - A-share performance from December 31, 2024, to September 8, 2025, shows significant gains for companies like Rongchang Bio (+208.87%) and Yifang Bio (+188.72%) [5][16] - R&D investment among 32 sample innovative drug companies reached 33.6 billion yuan in H1 2025, reflecting a year-on-year increase of 4.91% [21] - Sales and R&D expense ratios for 21 sample companies have been declining from 2021 to H1 2025, indicating a trend towards profitability [27] - The sales revenue of 17 commercialized innovative drug companies reached 56.6 billion yuan in H1 2025, a 30% increase year-on-year [31] Outlook: Valuation Breakthrough Under Engineer Dividend - Domestic policies are driving the industry upward, with continuous implementation of supportive measures for innovative drug development [38] - The report notes that the value of Chinese innovative drugs is increasingly recognized by multinational corporations (MNCs), enhancing their international competitiveness [41] - The report anticipates a significant increase in the number of approved innovative drugs, with 44 new Class 1 innovative drugs approved by CDE by September 15, 2025 [48] Investment Strategy: Positive Profitability Improvement and Valuation Breakthrough - The report recommends focusing on global blockbuster potentials, with Zebutini expected to exceed $2.6 billion in sales in 2024 [52] - Companies such as Kelun Biotech, Innovent Biologics, and others are highlighted as key investment targets due to their strong growth potential [52] - The report emphasizes the ongoing trend of profitability improvement, with companies like BeiGene expected to turn profitable in 2025 [52]

来源：新浪基金∞工作室 9月23日，港股创新药ETF（159567）跌1.58%，成交额10.76亿元。当日份额增加5500.00万份，最新份 额为82.17亿份，近20个交易日份额增加19.63亿份。最新资产净值计算值为76.64亿元。 港股创新药ETF（159567）业绩比较基准为国证港股通创新药指数收益率(经估值汇率调整)，管理人为 银华基金管理股份有限公司，基金经理为马君，成立（2024-01-03）以来回报为86.54%，近一个月回报 为-7.18%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...

建议关注：①全球大单品：百济神州(06160)，科伦博泰生物(06990)，信达生物(01801)，康方生物 (09926)，三生制药(01530)，百利天恒(688506.SH)，新诺威(300765.SZ)，石药集团(01093)，翰森制药 (03692)，中国生物制药(01177)，一品红(300723.SZ)，映恩生物(09606)； ②全球BIC潜力：益方生物(688382.SH)，泽璟制药(688266.SH)，基石药业(01592)，苑东生物 (688513.SH)，科济药业(02171)，来凯医药(02105)，复宏汉霖(02696)，再鼎医药(09688)，和黄医药 (00013)，药捷安康(02617)，加科思(01167)，歌礼制药(01672)； ③国内大单品：舒泰神(300204.SZ)，艾力斯(688578.SH)，云顶新耀(01952)，恒瑞医药(600276.SH)，贝 达药业(300558.SZ)，华领医药(02552)； ④资产价值：和铂医药(02142)，和誉(02256)。 立足现在：进军全球商业化，大量优质项目将继续推高产业发展 中国创新药行业已形成以领头企业为引领、 ...

Macro Economy - The People's Bank of China Governor Pan Gongsheng met with Ray Dalio, founder of Bridgewater Associates, to discuss international economic conditions and financial market dynamics [3] - The State Council Information Office announced that China has established the largest and highest-quality education system, with over 12 million children benefiting from the free preschool policy this year [3] - Domestic refined oil price adjustments have been suspended for the sixth time this year, with the latest monitoring indicating a price change of less than 50 yuan per ton [3] - The Ministry of Industry and Information Technology aims to accelerate the development of emerging pillar industries and establish a growth mechanism for future industry investments [3] - The State Administration for Market Regulation has taken measures against Toutiao and UC for displaying harmful information and extreme sensitive content [4] Investment News - A-shares experienced wide fluctuations, with major banks rising by 2% and semiconductor equipment stocks hitting historical highs, while stablecoins and tourism sectors saw significant declines [6] - The Hong Kong Hang Seng Index closed down 0.7%, with net selling of 4.069 billion HKD from southbound funds [6] - The A-share market marked the one-year anniversary of the "9.24" rally, with the Shanghai Composite Index up nearly 40% and the Shenzhen Component Index up over 60% [6] - A new wave of fee reductions has begun in money market funds, with Tianhong's Yu'ebao reducing its custody fee for the first time in over ten years [7] Company Movements - Tianpu Co., Ltd. has seen its stock price hit the limit up for 15 consecutive trading days, with a cumulative increase of 317.72%, leading to a suspension of trading [9] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange, with details yet to be confirmed [10] - Zhiyuan Robotics has fully opened its GO-1 general embodiment model, marking a significant milestone in embodied intelligence technology [10] - Hongmeng Zhixing announced the launch of its new model, the Shangjie H5, with a starting price of 159,800 yuan and over 160,000 pre-orders [10] - Ruifeng New Materials indirectly invested 90 million yuan in Moer Thread through a fund, with a total investment amount of 29.735 million yuan [10] US Market Overview - On September 23, US stock indices closed lower, with the Dow down 0.19% and the S&P 500 down 0.55%, led by declines in major tech stocks [11] - Federal Reserve Chairman Jerome Powell indicated that the risks in the job market were a key reason for the recent interest rate cut [11] - The OECD projected a global economic growth rate of 3.2% for 2025, an increase of 0.3 percentage points from previous forecasts [11]

建信基金特别策划科技投资系列内容，为大家系统梳理了科技领域投资的方方面面。 CIS 今年以来，以人工智能和创新药为代表的科技成长赛道，成为引领A股结构性行情的主引擎。展望后 市，科技和先进制造等成长方向或仍是长期关注重点。 ...